Evaluator-blinded trial evaluating nurse-led immunotherapy DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) and accompanying process evaluation: study protocol for a cluster randomised controlled trial

Anne Christin Rahn, Sascha Köpke, Jürgen Kasper, Eik Vettorazzi, Ingrid Mühlhauser, Christoph Heesen, Anne Christin Rahn, Sascha Köpke, Jürgen Kasper, Eik Vettorazzi, Ingrid Mühlhauser, Christoph Heesen

Abstract

Background: Multiple sclerosis is a chronic neurological condition usually starting in early adulthood and regularly leading to severe disability. Immunotherapy options are growing in number and complexity, while costs of treatments are high and adherence rates remain low. Therefore, treatment decision-making has become more complex for patients. Structured decision coaching, based on the principles of evidence-based patient information and shared decision-making, has the potential to facilitate participation of individuals in the decision-making process. This cluster randomised controlled trial follows the assumption that decision coaching by trained nurses, using evidence-based patient information and preference elicitation, will facilitate informed choices and induce higher decision quality, as well as better decisional adherence.

Methods/design: The decision coaching programme will be evaluated through an evaluator-blinded superiority cluster randomised controlled trial, including 300 patients with suspected or definite relapsing-remitting multiple sclerosis, facing an immunotherapy decision. The clusters are 12 multiple sclerosis outpatient clinics in Germany. Further, the trial will be accompanied by a mixed-methods process evaluation and a cost-effectiveness study. Nurses in the intervention group will be trained in shared decision-making, coaching, and evidence-based patient information principles. Patients who meet the inclusion criteria will receive decision coaching (intervention group) with up to three face-to-face coaching sessions with a trained nurse (decision coach) or counselling as usual (control group). Patients in both groups will be given access to an evidence-based online information tool. The primary outcome is 'informed choice' after six months, assessed with the multi-dimensional measure of informed choice including the sub-dimensions risk knowledge (questionnaire), attitude concerning immunotherapy (questionnaire), and immunotherapy uptake (telephone survey). Secondary outcomes include decisional conflict, adherence to immunotherapy decisions, autonomy preference, planned behaviour, coping self-efficacy, and perceived involvement in coaching and decisional encounters. Safety outcomes are comprised of anxiety and depression and disease-specific quality of life.

Discussion: This trial will assess the effectiveness of a new model of patient decision support concerning MS-immunotherapy options. The delegation of treatment information provision from physicians to trained nurses bears the potential to change current doctor-focused practice in Germany.

Trial registration: Current Controlled Trials (identifier: ISRCTN37929939 ), May 27, 2014.

Figures

Figure 1
Figure 1
The DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) trial programme.
Figure 2
Figure 2
DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) trial flow.
Figure 3
Figure 3
Overview of the process evaluation steps (from Grantet al. [70]).

References

    1. World Health Organization and Multiple Sclerosis International Federation. Atlas multiple sclerosis resources in the world 2008. World Health Organization. 2008. . Accessed 2 March 2015.
    1. MesH. Multiple sclerosis. National Center for Biotechnology Information, Bethesda. . Accessed 2 March 2015.
    1. Deutsche Gesellschaft für Neurologie/Krankheitsbezogenes Kompetenznetz Multiple Sklerose: Leitlinie zur Diagnose und Therapie der MS. 2012. . Accessed 2 March 2015.
    1. Petersen G. Regionale Unterschiede in der Prävalenz und Pharmakotherapie von Multipler Sklerose. AGENS Methodenworkshop, March 2013, Berlin. . Accessed 2 March 2015.
    1. Noyes K, Bajorska A, Chappel A, Schwid SR, Mehta LR, Weinstock-Guttman B, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology. 2011;77:355–63. doi: 10.1212/WNL.0b013e3182270402.
    1. Kobelt G, Berg J, Lindgren P, Fredrikson S, Jonsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2006;77:918–26. doi: 10.1136/jnnp.2006.090365.
    1. Amato MP, Portaccio E. Truly benign multiple sclerosis is rare: let’s stop fooling ourselves − yes. Mult Scler. 2012;18:13–4. doi: 10.1177/1352458511431732.
    1. Hawkins S. Truly benign multiple sclerosis is rare: let's stop fooling ourselves–no. Mult Scler. 2012;18:11–2. doi: 10.1177/1352458511431717.
    1. Boggild M, Palace J, Barton P, Ben-Shlomo Y, Bregenzer T, Dobson C, et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ. 2009;339:b4677. doi: 10.1136/bmj.b4677.
    1. Bruce JM, Lynch SG. Multiple sclerosis: MS treatment adherence − how to keep patients on medication? Nat Rev Neurol. 2011;7:421–2. doi: 10.1038/nrneurol.2011.106.
    1. Barratt A. Evidence based medicine and shared decision making: the challenge of getting both evidence and preferences into health care. Patient Educ Couns. 2008;73:407–12. doi: 10.1016/j.pec.2008.07.054.
    1. Heesen C, Kleiter I, Nguyen F, Schäffler N, Kasper J, Köpke S, et al. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. Mult Scler. 2010;16:1507–12. doi: 10.1177/1352458510379819.
    1. Gerst T. Künftiger Bedarf an Ärzten: Verwirrende Zahlenspiele. Dtsch Arztebl Int. 2013;110:1894.
    1. Hartung HP, Ross AP. European nurse survey demonstrates significant disparities in nursing of multiple sclerosis patients and the need to benchmark standards for improved patient care. Mult Scler. 2010;1:S331.
    1. Thompson H, Gray O. Consultant Neurologist or specialist nurse? The role of a specialist nurse-led MS clinic for patients on disease-modifying therapy. Mult Scler. 2010;1:S171.
    1. Stacey D, Kryworuchko J, Belkora J, Davison BJ, Durand MA, Eden KB, et al. Coaching and guidance with patient decision aids: a review of theoretical and empirical evidence. BMC Med Inform Decis Mak. 2013;13(Suppl 2):S11. doi: 10.1186/1472-6947-13-S2-S11.
    1. Stacey D, Kryworuchko J, Bennett C, Murray MA, Mullan S, Légaré F. Decision coaching to prepare patients for making health decisions: a systematic review of decision coaching in trials of patient decision AIDS. Med Decis Making. 2012;32:E22–33. doi: 10.1177/0272989X12443311.
    1. Stacey D, Bennett CL, Barry MJ, Col NF, Eden KB, Holmes-Rovner M, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2011:CD001431.
    1. Hamann J, Langer B, Winkler V, Busch R, Cohen R, Leucht S, et al. Shared decision making for in-patients with schizophrenia. Acta Psychiatr Scand. 2006;114:265–73. doi: 10.1111/j.1600-0447.2006.00798.x.
    1. Kennedy AD, Sculpher MJ, Coulter A, Dwyer N, Rees M, Abrams KR, et al. Effects of decision aids for menorrhagia on treatment choices, health outcomes, and costs: a randomized controlled trial. JAMA. 2002;288:2701–8. doi: 10.1001/jama.288.21.2701.
    1. Lerman C, Biesecker B, Benkendorf JL, Kerner J, Gomez-Caminero A, Hughes C, et al. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. J Natl Cancer Inst. 1997;89:148–57. doi: 10.1093/jnci/89.2.148.
    1. Stacey D, Murray MA, Légaré F, Sandy D, Menard P, O’Connor A. Decision coaching to support shared decision making: a framework, evidence, and implications for nursing practice, education, and policy. Worldviews Evid Based Nurs. 2008;5:25–35. doi: 10.1111/j.1741-6787.2007.00108.x.
    1. Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. doi: 10.1136/bmj.e7586.
    1. Campbell MK, Piaggio G, Elbourne DR, Altman DG, CONSORT Group CONSORT 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. doi: 10.1136/bmj.e5661.
    1. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P, CONSORT Group Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med. 2008;148:295–309. doi: 10.7326/0003-4819-148-4-200802190-00008.
    1. Stacey D, Légaré F, Col NF, Bennett CL, Barry MJ, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2014;1
    1. Légaré F, Stacey D, Turcotte S, Cossi MJ, Kryworuchko J, Graham ID, et al. Interventions for improving the adoption of shared decision making by healthcare professionals. Cochrane Database Syst Rev. 2014;9
    1. Stacey D, O’Connor AM, Graham ID, Pomey MP. Randomized controlled trial of the effectiveness of an intervention to implement evidence-based patient decision support in a nursing call centre. J Telemed Telecare. 2006;12:410–5. doi: 10.1258/135763306779378663.
    1. van Peperstraten A, Nelen W, Grol R, Zielhuis G, Adang E, Stalmeier P, et al. The effect of a multifaceted empowerment strategy on decision making about the number of embryos transferred in in vitro fertilisation: randomised controlled trial. BMJ. 2010;341:c2501. doi: 10.1136/bmj.c2501.
    1. Myers RE, Daskalakis C, Kunkel EJ, Cocroft JR, Riggio JM, Capkin M, et al. Mediated decision support in prostate cancer screening: a randomized controlled trial of decision counseling. Patient Educ Couns. 2011;83:240–6. doi: 10.1016/j.pec.2010.06.011.
    1. Köpke S, Solari A, Khan F, Heesen C, Giordano A. Information provision for people with multiple sclerosis. Cochrane Database Syst Rev. 2014;4
    1. Heesen C, Solari A, Giordano A, Kasper J, Köpke S. Decisions on multiple sclerosis immunotherapy: new treatment complexities urge patient engagement. J Neurol Sci. 2011;306:192–7. doi: 10.1016/j.jns.2010.09.012.
    1. Golan D, Somer E, Dishon S, Cuzin-Disegni L, Miller A. Impact of exposure to war stress on exacerbations of multiple sclerosis. Ann Neurol. 2008;64:143–8. doi: 10.1002/ana.21409.
    1. Mohr DC, Goodkin DE, Masuoka L, Dick LP, Russo D, Eckhardt J, et al. Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis. Mult Scler. 1999;5:192–7. doi: 10.1177/135245859900500309.
    1. Köpke S, Kasper J, Mühlhauser I, Nubling M, Heesen C. Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial. Mult Scler. 2009;15:96–104. doi: 10.1177/1352458508095921.
    1. Kasper J, Köpke S, Mühlhauser I, Nubling M, Heesen C. Informed shared decision making about immunotherapy for patients with multiple sclerosis (ISDIMS): a randomized controlled trial. Eur J Neurol. 2008;15:1345–52. doi: 10.1111/j.1468-1331.2008.02313.x.
    1. Giovannoni G, Rhoades RW. Individualizing treatment goals and interventions for people with MS. Curr Opin Neurol. 2012;25(Suppl):S20–7. doi: 10.1097/01.wco.0000413321.32834.aa.
    1. Köpke S, Kern S, Ziemssen T, Berghoff M, Kleiter I, Marziniak M, et al. Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry. 2014;85:411–8. doi: 10.1136/jnnp-2013-306441.
    1. Köpke S, Backhus I, Kasper J, Brandt A, Bender G, Flachenecker P, et al. Patient education program on immunotherapy for persons with relapsing Multiple sclerosis during rehabilitation – multi-center controlled trial (ISRCTN83438362). 7th International Shared Decision Making Conference; 2013 April 16–19; Lima, Peru. . Accessed 2 March 2015.
    1. Christopherson JM, Moore K, Foley FW, Warren KG. A comparison of written materials vs materials and counselling for women with sexual dysfunction and multiple sclerosis. J Clin Nurs. 2006;15:742–50. doi: 10.1111/j.1365-2702.2005.01437.x.
    1. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008;337:a1655. doi: 10.1136/bmj.a1655.
    1. Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol. 2012;11:157–69. doi: 10.1016/S1474-4422(11)70274-5.
    1. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302. doi: 10.1002/ana.22366.
    1. Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (Or it takes at least two to tango) Soc Sci Med. 1997;44:681–92. doi: 10.1016/S0277-9536(96)00221-3.
    1. Multiple Sklerose Tagesklinik und Ambulanz. . Accessed 2 March 2015.
    1. Elwyn G, Edwards A, Wensing M, Hibbs R, Wilkinson C, Grol R. Shared decision making observed in clinical practice: visual displays of communication sequence and patterns. J Eval Clin Pract. 2001;7:211–21. doi: 10.1046/j.1365-2753.2001.00286.x.
    1. Berger B, Steckelberg A, Meyer G, Kasper J, Mühlhauser I. Training of patient and consumer representatives in the basic competencies of evidence-based medicine: a feasibility study. BMC Med Educ. 2010;10:16. doi: 10.1186/1472-6920-10-16.
    1. Köpke S, Richter T, Kasper J, Mühlhauser I, Flachenecker P, Heesen C. Implementation of a patient education program on multiple sclerosis relapse management. Patient Educ Couns. 2012;86:91–7. doi: 10.1016/j.pec.2011.03.013.
    1. Geiger F, Liethmann K, Hoffmann F, Paschedag J, Kasper J. Investigating a training supporting Shared Decision Making (IT’S SDM 2011): study protocol for a randomized controlled trial. Trials. 2011;12:232.
    1. Liethmann K, Kasper J, Geiger F. Investigating a training supporting shared decision-making: IT’S SDM. Multiperspective results from a multicenter RCT. In International Conference on Communication in Health Care; Amsterdam. 2014. .
    1. Heesen C, Kasper J, Schäffler N, Bingel U, Rosenkranz M, Hamann J, et al. Shared decision making in der neurologie – wieso? Wann? Wie viel? Neurol Rehabil. 2012;18:205–13.
    1. Heesen C, Köpke S, Solari A, Geiger F, Kasper J. Patient autonomy in multiple sclerosis–possible goals and assessment strategies. J Neurol Sci. 2013;331:2–9. doi: 10.1016/j.jns.2013.02.018.
    1. Heesen C, Köpke S, Kasper J, Drulovic J, Van Nunen A, Vahter L, et al. Multi-language translation and cross-cultural adaptation of the patient-reported relapsing-remitting MS risk knowledge questionnaire on immunotherapy (RRMS-IRKQ): Methodological issues (#52) Mult Scler. 2012;18(5):S25–6. doi: 10.1177/1352458512444211.
    1. O’Connor AM, Jacobsen MJ, Stacey D. An evidence-based approach to managing women’s decisional conflict. J Obstet Gynecol Neonatal Nurs. 2002;31:570–81. doi: 10.1111/j.1552-6909.2002.tb00083.x.
    1. LeBlanc A, Kenny DA, O’Connor AM, Légaré F. Decisional conflict in patients and their physicians: a dyadic approach to shared decision making. Med Decis Making. 2009;29:61–8. doi: 10.1177/0272989X08327067.
    1. Degner LF, Sloan JA, Venkatesh P. The Control Preferences Scale. Can J Nurs Res. 1997;29:21–43.
    1. Kasper J, Köpke S, Fischer K, Schäffler N, Backhus I, Solari A, et al. Applying the theory of planned behaviour to multiple sclerosis patients’ decisions on disease modifying therapy − questionnaire concept and validation. BMC Med Inform Decis Mak. 2012;12:60. doi: 10.1186/1472-6947-12-60.
    1. Chesney MA, Neilands TB, Chambers DB, Taylor JM, Folkman S. A validity and reliability study of the coping self-efficacy scale. Br J Health Psychol. 2006;11:421–37. doi: 10.1348/135910705X53155.
    1. Kasper J, Hoffmann F, Heesen C, Köpke S, Geiger F. MAPPIN’SDM − the multifocal approach to sharing in shared decision making. PLoS One. 2012;7:e34849. doi: 10.1371/journal.pone.0034849.
    1. Bova C, Fennie KP, Watrous E, Dieckhaus K, Williams AB. The health care relationship (HCR) trust scale: development and psychometric evaluation. Res Nurs Health. 2006;29:477–88. doi: 10.1002/nur.20158.
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70. doi: 10.1111/j.1600-0447.1983.tb09716.x.
    1. Gold SM, Heesen C, Schulz H, Guder U, Mönch A, Gbadamosi J, et al. Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS) Mult Scler. 2001;7:119–30. doi: 10.1177/135245850100700208.
    1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology. 1983;33:1444–52. doi: 10.1212/WNL.33.11.1444.
    1. Parmenter BA, Weinstock-Guttman B, Garg N, Munschauer F, Benedict RH. Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test. Mult Scler. 2007;13:52–7. doi: 10.1177/1352458506070750.
    1. Gelman A, Hill J. Data analysis using regression and multilevel/hierarchical models. Cambridge: Cambridge University Press; 2007.
    1. Altman DG. Missing outcomes in randomized trials: addressing the dilemma. Open Med. 2009;3:e51–3.
    1. Alshurafa M, Briel M, Akl EA, Haines T, Moayyedi P, Gentles SJ, et al. Inconsistent definitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature. PLoS One. 2012;7:e49163. doi: 10.1371/journal.pone.0049163.
    1. Thabane L, Mbuagbaw L, Zhang S, Samaan Z, Marcucci M, Ye C, et al. A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. BMC Med Res Methodol. 2013;13:92. doi: 10.1186/1471-2288-13-92.
    1. Linnan L, Steckler A. Process evaluation for public health interventions and research. San Francisco: Jossey-Bass; 2002. Process evaluation for public health interventions and research: an overview; pp. 1–23.
    1. Grant A, Treweek S, Dreischulte T, Foy R, Guthrie B. Process evaluations for cluster-randomised trials of complex interventions: a proposed framework for design and reporting. Trials. 2013;14:15. doi: 10.1186/1745-6215-14-15.
    1. Ferlie EB, Shortell SM. Improving the quality of health care in the United Kingdom and the United States: a framework for change. Milbank Q. 2001;79:281–315. doi: 10.1111/1468-0009.00206.
    1. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn’t. BMJ. 1996;312:71–2. doi: 10.1136/bmj.312.7023.71.
    1. Klafki W. Neue Studien zur Bildungstheorie und Didaktik. Beiträge zur kritisch-konstruktiven Didaktik. 5. Beltz Verlag: Weinheim und Basel; 1996.
    1. Roth H. Pädagogische Psychologie des Lehrens und Lernens. 13. Hermann Schroedel Verlag KG: Hannover; 1971.
    1. Ajzen I. The theory of planned behaviour: reactions and reflections. Psychol Health. 2011;26:1113–27. doi: 10.1080/08870446.2011.613995.
    1. Bunge M, Mühlhauser I, Steckelberg A. What constitutes evidence-based patient information? Overview of discussed criteria. Patient Educ Couns. 2010;78:316–28. doi: 10.1016/j.pec.2009.10.029.
    1. Johnson RB, Onwuegbuzie AJ, Turner LA. Toward a definition of mixed methods research. J Mixed Methods Res. 2007;1:112–33. doi: 10.1177/1558689806298224.
    1. Creswell JW. Plano Clark VL Designing and conducting mixed methods research. 2. Thousand Oaks: Sage publications; 2011.
    1. Stacey D, Chambers SK, Jacobsen MJ, Dunn J. Overcoming barriers to cancer-helpline professionals providing decision support for callers: an implementation study. Oncol Nurs Forum. 2008;35:961–9. doi: 10.1188/08.ONF.961-969.
    1. Hopf C. Qualitative Interviews in der Sozialforschung. Ein Überblick. In: Flick U, editor. Handbuch qualitative Sozialforschung: Grundlagen, Konzepte, Methoden und Anwendungen. 2. Beltz: Weinheim; 2005.
    1. Burnard P. A method of analysing interview transcripts in qualitative research. Nurse Educ Today. 1991;11:461–6. doi: 10.1016/0260-6917(91)90009-Y.
    1. Marteau TM, Dormandy E, Michie S. A measure of informed choice. Health Expect. 2001;4:99–108. doi: 10.1046/j.1369-6513.2001.00140.x.
    1. O’Connor AM. Validation of a decisional conflict scale. Med Decis Making. 1995;15:25–30. doi: 10.1177/0272989X9501500105.
    1. Buchholz A, Hölzel L, Kriston L, Simon D, Härter M. Die Decisional Conflict Scale in deutscher Sprache (DCS-D) - Dimensionale Struktur in einer Stichprobe von Hausarztpatienten. Klin. Diagnostik u. Evaluation. 2011;4:15–30.
    1. Heesen C, Meuth S, Zingler VC, Wernsdoerfer C, Köpke S, Kleiter I, et al. Percept: a prospective multicenter observational study on benefit/risk perception of natalizumab in neurologists and their patients in Germany. Abstracts of the XXI World Congress of Neurolog. J Neurol Sci. 2013;333(Suppl 1):e379. doi: 10.1016/j.jns.2013.07.1378.
    1. Solari A, Giordano A, Kasper J, Drulovic J, van Nunen A, Vahter L, et al. Role preferences of people with multiple sclerosis: image-revised, computerized self-administered version of the control preference scale. PLoS One. 2013;8:e66127. doi: 10.1371/journal.pone.0066127.
    1. Böhm J. Patientenselbstbewertung neurologischer Beeinträchtigung bei Multipler Sklerose – welche körperlichen Funktionen sind die Wertvollsten? [PhD thesis] Hamburg: University Medical Center Hamburg-Eppendorf, Institute of Neuroimmunology and Multiple Sclerosis (INIMS); 2011.
    1. Mikula P, Nagyova I, Krokavcova M, Vitkova M, Rosenberger J, Szilasiova J, et al. Coping and its importance for quality of life in patients with multiple sclerosis. Disabil Rehabil. 2014;36:732–6. doi: 10.3109/09638288.2013.808274.
    1. Bova C, Route PS, Fennie K, Ettinger W, Manchester GW, Weinstein B. Measuring patient-provider trust in a primary care population: refinement of the health care relationship trust scale. Res Nurs Health. 2012;35:397–408. doi: 10.1002/nur.21484.
    1. Schäffler N, Schönberg P, Stephan J, Stellmann JP, Gold SM, Heesen C. Comparison of patient-reported outcome measures in multiple sclerosis. Acta Neurol Scand. 2013;128:114–21. doi: 10.1111/ane.12083.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다